Friday, 6 November 2026European Markets

MELHUS SPAREBANK And CRCAM BRIE PIC2CCI Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - melhus sparebank (melg.ol) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
melhus sparebank (melg.ol) kr156.00 6.92% 10.56%
crcam brie pic2cci (crbp2.pa) €18.80 5.48% 3.64%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. melhus sparebank (melg.ol)

6.92% forward dividend yield and 10.56% return on equity

melhus sparebank, a savings bank, provides various banking products and services to companies, agriculture customers, and private individuals in norway. the company offers savings accounts; construction and business loans; bank guarantee, overdraft, and leasing services; and credit and bank cards. it also provides various insurance products for liability, health, personnel, occupational injury, travel, accident, business, store, data attack, property damage, craftsman, homeowners, office, vehicle, and farms; savings and pension products; payment services; and online and mobile banking services. the company operates through branch offices in central trondheim, heimdal, ler, and korsvegen. melhus sparebank was founded in 1840 and is headquartered in melhus, norway.

earnings per share

as for profitability, melhus sparebank has a trailing twelve months eps of kr16.44.

pe ratio

melhus sparebank has a trailing twelve months price to earnings ratio of 9.49. meaning, the purchaser of the share is investing kr9.49 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.56%.

more news about melhus sparebank.

2. crcam brie pic2cci (crbp2.pa)

5.48% forward dividend yield and 3.64% return on equity

caisse régionale de crédit agricole mutuel brie picardie société coopérative provides a range of banking and financial products and services to individuals, farmers, professionals, businesses, and local authorities in france. it offers savings support comprising monetary, bonds, and securities; and life insurance investments, as well as housing and consumer loans; payment services; and property and casualty insurance, provident insurance products, and life insurance products. the company was founded in 2005 and is headquartered in amiens, france. caisse régionale de crédit agricole mutuel brie picardie société coopérative operates as a subsidiary of crédit agricole s.a.

pe ratio

crcam brie pic2cci has a trailing twelve months price to earnings ratio of 1.67. meaning, the purchaser of the share is investing €1.67 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.64%.

yearly top and bottom value

crcam brie pic2cci's stock is valued at €18.80 at 07:30 est, below its 52-week high of €20.10 and way above its 52-week low of €16.90.

more news about crcam brie pic2cci.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com